Back

Novartis AG ADR

Ticker: NVS ISIN: US66987V1098
Add to portfolio Portfolio analysis in 2min
Stock Large-cap Dividend payer Trading above 200-day average Near 52-week high
Market cap
$221.49B
P/E
19.14
Forward P/E
13.61
Profit margin
23.09%
Revenue growth QoQ
15.10%
Div. yield
3.56%
Beta
0.55
$159.98 1.24%
Price as of 2026-08-25 · NYSE

Performance by timeframe

Rolling returns
1 Month +2.48%
6 Months -1.20%
1 Year +30.17%
5 Years +15.97% p.a.+109.64%
10 Years +12.45% p.a.+223.17%
Since inception +10.20% p.a.+1,029.92%
Calendar year returns
YTD +19.57%
2025 +46.95%
2024 +0.02%
2023 +16.14%
2022 +8.06%
2021 -3.65%

Key stats

Market cap
221.49B
P/E
19.14
Dividend yield
3.56%
Beta
0.55
52-week range
92.72 - 116.72
50-day MA
109.72
200-day MA
108.92
Section 1

Business overview

Company profile data from fundamentals.

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Sector Healthcare
Industry Drug Manufacturers - General
Country Switzerland
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 26.28%
ROA 10.09%
Profit margin 23.09%
Operating margin 29.94%
PEG ratio 1.30
Revenue/share TTM 25.63
Revenue TTM 51.72B
EBITDA 20.66B
Gross profit TTM 38.91B
Beta 0.55

Valuation

Trailing P/E 19.14
Forward P/E 13.61
P/B 5.03
P/S 4.28
EV/EBITDA 11.49
EV/Revenue 4.60
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 8.62
Quarterly earnings growth -65.60%
Revenue TTM 51.72B
Reported quarters 99
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 3.56%
Forward annual div. yield 3.56%
Dividend per share 3.8620
Payout ratio 51.14%
Ex-dividend date 2025-03-12
Split factor 1116:1000
Last split date 2019-04-09
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price $112.26
Analyst rating 2.8462

Ownership & short interest

Shares outstanding 1.98B
Shares float 1.88B
Institutional ownership 6.71%
Insider ownership 0.30%
Short ratio 1.27
Short % of float 0.16%

Details

Instrument metadata and source update timestamps.

Symbol NVS
Name Novartis AG ADR
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US66987V1098
Country USA
Code + exchange NVS.NYSE
Last price date 2025-04-25
Fundamentals updated 2025-04-26

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.